Validation of the Prostate Cancer Biomarker Stockholm3 for Improved Disease Detection and Classification in the Swiss Population

University Hospital, Basel, Switzerland1 site in 1 country380 target enrollmentJanuary 1, 2020

ConditionsProstate Cancer Localized Carcinoma

Overview

Phase: N/A
Intervention: Not specified
Conditions: Prostate Cancer
Sponsor: University Hospital, Basel, Switzerland
Enrollment: 380
Locations: 1
Primary Endpoint: Cancer detection
Status: Completed
Last Updated: 2 years ago

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

The purpose of this study is to collect blood samples to investigate the prognostic performance of the STHLM3 test in a population of Swiss and German men suspected of harbouring prostate cancer based on a combination of elevated PSA levels (e.g. >2.5 ng/ml) and/or pathological digital rectal examination and/or MRI-findings.

Registry

clinicaltrials.gov

Start Date

January 1, 2020

End Date

October 1, 2023

Last Updated

2 years ago

Study Type

Observational

Sex

Male

Investigators

Sponsor

University Hospital, Basel, Switzerland

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•Planned prostate biopsy due to suspicion of prostate cancer (usually due to a combination of elevated PSA levels \[e.g. \>2.5 ng/ml\] and/or pathological digital rectal examination and/or MRI-findings)
•Written informed consent by the participant